You are here

Novartis

Two years on, Allergan’s $1.7B NASH drug still looks weak — at best

Endpoints

Fri, 09/22/17 - 11:16 am

Pharma executives wary of value-based deals, but see the potential benefits: PwC

Fierce Pharma

Fri, 09/22/17 - 11:13 am

value-based contracts

New pharma CEOs to face payer, pricing challenges

Medical Marketing and Media

Thu, 09/21/17 - 10:15 pm

Teva Pharmaceutical

Vasant Narasimham

On CAR-T’s Edge, Seattle Researchers Plot to Bypass Novartis Therapy

Xconomy

Tue, 09/19/17 - 08:43 am

Seattle Children's

pediatric cancer

Novartis touts 5-year Cosentyx data as it works to hold top spot in psoriasis

Fierce Pharma

Wed, 09/13/17 - 09:43 pm

#ESMO17: Eli Lilly sets the stage for a CDK 4/6 showdown with Pfizer, Novartis — but not exactly to its advantage

Endpoints

Mon, 09/11/17 - 09:17 am

An accurate analysis of the differences between Swiss companies Roche and Novartis

GoInPharma

Sat, 09/9/17 - 01:22 pm

Departing Novartis CEO Sets His Eyes On Silicon Valley

Forbes

Thu, 09/7/17 - 09:51 am

Novartis charged much more in the U.S. for some drugs than in other countries

Stat

Tue, 09/5/17 - 10:05 pm

New Novartis CEO Narasimhan will face plenty of obstacles despite CAR-T triumph

Fierce Biotech

Tue, 09/5/17 - 11:10 am

Novartis follows up on big CAR-T win by naming Vas Narasimhan as its new CEO

Endpoints

Mon, 09/4/17 - 10:13 am

At $475,000, new cancer drug raises thorny questions about drug pricing — and value

Stat

Mon, 09/4/17 - 10:11 am

Parkinson's Now a Hot Therapeutic Area: What's Up Lately?

Yahoo/Zacks.com

Sat, 09/2/17 - 11:11 am

Parkinson's Disease

Teva Pharmaceutial

Adamas Pharmaceuticals

Novartis CEO: Here's How We Handled A Milestone In Pediatric Cancer

Forbes

Fri, 09/1/17 - 04:08 pm

pediatric cancer

Landmark approval won, Novartis' next test is scaling CAR-T manufacturing

BioPharma Dive

Fri, 09/1/17 - 11:24 am

drug manufacturing

Profit on $475,000 Novartis cancer drug could be a while coming

Yahoo/Reuters

Fri, 09/1/17 - 11:15 am

Why bluebird bio Inc Continued Its March Higher Again Today

Motley Fool

Thu, 08/31/17 - 10:13 pm

Gilead Sciences

Novartis $475,000 Price Tag Sets the Stage for a Price War With Gilead Sciences

Motley Fool

Thu, 08/31/17 - 10:11 pm

Gilead Sciences

Novartis, UCSF researchers urge FDA to clean up its messy adverse events database

Endpoints

Thu, 08/31/17 - 10:50 am

A Cancer Doc Weighs In On CAR-T, Precision Medicine And Pricing Debates

Forbes

Thu, 08/31/17 - 09:17 am

precision medicine

Pages